Sodium Sulfate Anhydrous

Summary

Sodium Sulfate Anhydrous (CHEMBL233406) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 4
• Chemistry: 142.04 Da · Na2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL233406
Name	Sodium Sulfate Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	24436
ChEBI	CHEBI:32149
Molecular formula	Na2O4S
Molecular weight	142.04
InChIKey	PMZURENOXWZQFD-UHFFFAOYSA-L

SMILES: [O-]S(=O)(=O)[O-].[Na+].[Na+]

IUPAC name: disodium;sulfate

Also known as: Anhydrous sodium sulfate, E514, Mirabilite, Natrii sulfas anhydricus, NSC-403914, Sodium sulfate anhydrous, Sodium sulfate, anhydrous, dried, Sodium sulphate anhydrous, Sodium sulphate, sodium sulfate

Parent form; salt/anhydrous children: CHEMBL3989856

Patent coverage: 343,133 distinct patent families (821,191 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	2
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05570669	PHASE4	COMPLETED	Evaluation of Two Different Regimens of Colon Preparations for Advanced Cleaning.
NCT05877911	PHASE2	UNKNOWN	Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy
NCT02523911	Not specified	WITHDRAWN	Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening
NCT06051955	Not specified	UNKNOWN	Evaluation of an Oral Sodium Sulfate Solution for Patients With Prior Difficult or Incomplete Cleansing

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).